Abstract: A fibrin sealant product having a plurality of layers that each includes a dextran support and at least one fibrin sealant agent. The at least one fibrin sealant agent is placed on the dextran support to form each of the layers. The plurality of layers is placed in a stacked configuration to form the fibrin sealant product. A plurality of crimps is dispersed over a surface of the fibrin sealant product to retain the plurality of layers in a position with respect to each other.

Abstract: A method of sealing a durotomy from which cerebrospinal fluid is leaking. A durotomy sealant dressing is prepared by applying an active agent to a dextran base. The durotomy sealant dressing is applied to a durotomy. At least a portion of the durotomy sealant dressing dissolves. The durotomy is sealed with the dissolved durotomy sealant dressing to substantially prevent cerebrospinal fluid from flowing through the durotomy.

Abstract: A surgical joint replacement kit including a first joint replacement component and a surgical sealant. The first joint replacement component is capable of being implanted to replace a joint between a first bone and a second bone. The first bone is cut in conjunction with implanting the first joint replacement component. Cutting the first bone causes a bodily fluid to flow from the first bone. The surgical sealant includes an electrospun dextran base and an effective amount of at least one of fibrinogen and thrombin. The at least one of fibrinogen and thrombin is applied to the electrospun dextran base to form the surgical sealant. The surgical sealant is capable of staunching the flow of the bodily fluid from the first bone.

Abstract: A hemostatic product that includes a dry fibrinogen mixture, a dry thrombin mixture and a biologically tolerable liquid. The dry fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The dry thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the dry fibrinogen mixture and the dry thrombin mixture to form the hemostatic product.

Abstract: A fibrin sealant product having a plurality of layers that each includes a dextran support and at least one fibrin sealant agent. The at least one fibrin sealant agent is placed on the dextran support to form each of the layers. The plurality of layers is placed in a stacked configuration to form the fibrin sealant product. A plurality of crimps is dispersed over a surface of the fibrin sealant product to retain the plurality of layers in a position with respect to each other.

Abstract: A method of forming a hemostatic product. A solution is formed with a polymeric material. An electrospinning system is provided having a first nozzle and a second nozzle. The polymeric material solution is passed through the first nozzle and a hemostatic agent is passed through the second nozzle to form an electrospun fiber in which the polymeric material at least partially covers the hemostatic agent. The electrospun fiber is deposited on a support to form the hemostatic product.

Abstract: A hemostatic product that includes a fibrinogen mixture, a thrombin mixture and a biologically tolerable liquid. The fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the fibrinogen mixture and the thrombin mixture to form the hemostatic product.

Abstract: A method of sealing a durotomy from which cerebrospinal fluid is leaking. A durotomy sealant dressing is prepared by applying an active agent to a dextran base. The durotomy sealant dressing is applied to a durotomy. At least a portion of the durotomy sealant dressing dissolves. The durotomy is sealed with the dissolved durotomy sealant dressing to substantially prevent cerebrospinal fluid from flowing through the durotomy.

Abstract: A method of forming hemostatic sheets. Dextran and water are mixed to form a dextran-water mixture. The dextran-water mixture is formed into a first support layer. Fibrinogen and thrombin are mixed to form a fibrinogen and thrombin mixture. The fibrinogen and thrombin mixture is dispersed on the first support layer to form a hemostatic sheet.

Abstract: A method of forming a hemostatic product. A porous base is prepared that is capable of substantially dissolving when applied to a bleeding wound. A hemostatic agent is mixed with at least one salt to prepare a hemostatic mixture. The hemostatic mixture is dispersed on the porous base to form the hemostatic product.

Abstract: A method of causing delayed hemostasis. A hemostatic product is formed by applying a hemostatic agent to a dextran support. The hemostatic agent is provided with at least one of a reduced concentration and a reduce availability. The hemostatic product is applied to a wound from which blood is being discharged. At least one foreign object or pathogen is proximate the wound. Hemostasis is progressively caused so that blood continues to be discharged from the wound to cause the at least one foreign object or pathogen to move away from the wound.

Abstract: A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided. At least one hemostatic agent stabilizer is mixed with at least one hemostatic agent to form a hemostatic agent and stabilizer mixture. The at least one hemostatic agent includes at least one of thrombin and fibrinogen. The hemostatic agent and stabilizer mixture is associated with the dextran support. The hemostatic product is applied to the wound in which a bodily fluid is present. The at least one hemostatic agent is released from the hemostatic product to induce hemostasis in the wound.

Abstract: A hemostatic product that includes a dextran support, at least one hemostatic agent and at least one hemostatic agent stabilizer. The at least one hemostatic agent is selected from the group consisting of thrombin and fibrinogen. The at least one hemostatic agent is associated with the dextran support. The at least one hemostatic agent stabilizer is associated with the at least one hemostatic agent.

Abstract: A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided. At least one hemostatic agent stabilizer is mixed with at least one hemostatic agent to form a hemostatic agent and stabilizer mixture. The at least one hemostatic agent includes at least one of thrombin and fibrinogen. The hemostatic agent and stabilizer mixture is associated with the dextran support. The hemostatic product is applied to the wound in which a bodily fluid is present. The at least one hemostatic agent is released from the hemostatic product to induce hemostasis in the wound.

Abstract: A safety device includes an elongate tubular member formed of a buoyant material having gripping surfaces disposed on distal and proximal ends thereof. The elongate tubular member is positionable between initial and second positions. First and second appendages are disposed in mechanical cooperation with the proximal and distal ends of the elongate tubular member. A tether assembly is operably associated with the elongate tubular member and includes one or more couplings and a tether for releasably fixing the elongate tubular member in one or more second positions.

Abstract: A safety device includes an elongate tubular member formed of a buoyant material having gripping surfaces disposed on distal and proximal ends thereof. The elongate tubular member is positionable between initial and second positions. First and second appendages are disposed in mechanical cooperation with the proximal and distal ends of the elongate tubular member. A tether assembly is operably associated with the elongate tubular member and includes one or more couplings and a tether for releasably fixing the elongate tubular member in one or more second positions.

Abstract: Therapeutic devices and methods according to embodiments of the invention alleviate e.g. urinary incontinence in female and male patients. Suction or vacuum, for example, is applied to the genital region, clitoris or clitoral region, the external urethral orifice, and/or other designated areas, e.g. physically stimulating the sacral/pudendal nerves and/or nerve roots and alleviating incontinence. Such embodiments also can encourage or cause clitoral engorgement, or otherwise promote blood flow in the genital region. Vacuum or suction applied to e.g. the clitoris creates a negative pressure in the clitoris that is lower than the systolic blood pressure, tending to promote engorgement of the clitoris with blood. Aspects of the invention are applicable not only to treatment of urinary and fecal incontinence, but also to the treatment of female sexual dysfunction. Aspects of the invention are also applicable to treatment of male incontinence and male erectile dysfunction.

Abstract: Therapeutic devices and methods according to embodiments of the invention alleviate e.g. urinary incontinence in female and male patients. Suction or vacuum, for example, is applied to the genital region, clitoris or clitoral region, the external urethral orifice, and/or other designated areas, e.g. physically stimulating the sacral/pudendal nerves and/or nerve roots and alleviating incontinence. Such embodiments also can encourage or cause clitoral engorgement, or otherwise promote blood flow in the genital region. Vacuum or suction applied to e.g. the clitoris creates a negative pressure in the clitoris that is lower than the systolic blood pressure, tending to promote engorgement of the clitoris with blood. Aspects of the invention are applicable not only to treatment of urinary and fecal incontinence, but also to the treatment of female sexual dysfunction. Aspects of the invention are also applicable to treatment of male incontinence and male erectile dysfunction.

Abstract: Ultra fine polypropylene fibers having a length of 1-100 microns and a diameter of 0.05-2 microns are admixed with a polyester resin composition comprising a polyester resin of a polyhydric alcohol and an unsaturated polycarboxylic acid admixed with a solvent such as styrene in an amount effective to cause the resulting thickened composition to have a thixotropic index of 1.5-8. The resulting thickened composition is useful for building or repairing fiber glass-polyester boats. The incorporation of such ultrafine polypropylene fibers in an epoxy resin composition also thickens the epoxy resin composition and causes it to have a thixotropic index of about 1.5-8.